SCHEMBL3370984

SCHEMBL3370984

CC(C)(C)[Si](C)(C)OCCOc1cccc2c1nc(C(=O)O)n2CC(=O)Nc1ccc(Cl)cn1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.40
LMNA P02545 4/20 0.40
NPC1 O15118 4/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
TP53 P04637 2/20 0.40
NFKB1 P19838 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40
F10 P00742 2/20 0.39
ALDH1A1 P00352 2/20 0.38
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
TDP1 Q9NUW8 1/20 0.38
F2 P00734 2/20 0.38
TSHR P16473 3/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
HTT P42858 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
MAPT P10636 2/20 0.36
PKM P14618 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6016873 0.90 F10 (0.48) RAB9ALMNANPC1SMN1; SMN2TP53
SCHEMBL3371312 0.88 F10 (0.45) RAB9ALMNANPC1SMN1; SMN2TP53
SCHEMBL3371687 0.86 RAB9A (0.45) RAB9ALMNANPC1SMN1; SMN2TP53
SCHEMBL3370092 0.86 RAB9A (0.45) RAB9ALMNANPC1SMN1; SMN2TP53
SCHEMBL6016954 0.78 F10 (0.55) F10ALDH1A1F2
SCHEMBL3374046 0.77 ALDH1A1 (0.46) RAB9ALMNANPC1SMN1; SMN2TP53
SCHEMBL6016870 0.76 F10 (0.39) F10ALDH1A1F2
SCHEMBL3371014 0.76 F10 (0.42) RAB9ALMNANPC1SMN1; SMN2TP53
SCHEMBL3371004 0.74 LMNA (0.44) RAB9ALMNANPC1SMN1; SMN2TP53
SCHEMBL3367236 0.73 F10 (0.61) RAB9ALMNANPC1SMN1; SMN2F10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1636216-B1 BENZIMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS SANOFI AVENTIS DEUTSCHLAND (DE) 2010-07-21 EP disclosed
US-7741341-B2 Benzimidazole-derivatives as factor Xa inhibitors SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2010-06-22 US disclosed
EP-1636216-A1 BENZIMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS Sanofi-Aventis Deutschland GmbH (DE) 2006-03-22 EP disclosed
US-20050009829-A1 Benzimidazole-derivatives as factor Xa inhibitors AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2005-01-13 US disclosed
WO-2004101553-A1 BENZIMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2004-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009829-A1 Benzimidazole-derivatives as factor Xa inhibitors F12, F11, F5 RAB9A 1201/4885LMNA 141/4885NPC1 3517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.